The United States Patent and Trademark Office (USPTO) has issued patent US12583869B2, covering specific salt and crystal forms of an adenosine A2A receptor antagonist. The patent details the preparation method for these forms and their application in treating A2A receptor-related diseases, with the maleate salt structure specified. The patent was granted to CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD.

This patent grant signifies a new intellectual property right for the assignee, potentially impacting future drug development and manufacturing processes related to A2A receptor antagonists. While this is a patent grant and not a regulatory rule imposing direct compliance obligations on other entities, it establishes exclusive rights that may influence market entry and research activities in this therapeutic area. Companies operating in the pharmaceutical sector, particularly those involved in developing treatments for A2A receptor-related diseases, should be aware of this granted patent.